Zsofia Kuronya
Overview
Explore the profile of Zsofia Kuronya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roviello G, Molina-Cerrillo J, Massari F, Cerbone L, Fiala O, Fornarini G, et al.
Cancer Immunol Immunother
. 2025 Jan;
74(2):65.
PMID: 39752009
Introduction: Renal cell carcinoma (RCC) is one of the most common types of urogenital cancer. The introduction of immune-based combinations, including dual immune-checkpoint inhibitors (ICI) or ICI plus tyrosine kinase...
2.
Ciccarese C, Buttner T, Cerbone L, Zampiva I, Monteiro F, Basso U, et al.
Int J Cancer
. 2024 Sep;
155(11):2036-2046.
PMID: 39243397
Metastatic renal cell carcinoma (mRCC) carrying sarcomatoid features (sRCC) has aggressive biology and poor prognosis. First-line immunotherapy (IO)-based combinations have improved the outcome of clear cell RCC patients, including that...
3.
Melegh Z, Csernak E, Kohanka A, Rubovszkyne Gallai M, Bencze E, Szoke M, et al.
Magy Onkol
. 2024 Jul;
68(2):137-141.
PMID: 39013087
The best predictive marker for the expected efficacy of PARP inhibitor therapy is mutations in BRCA1/2 or other homologous recombination repair genes. These tests are part of routine molecular pathology...
4.
Toth E, Kuronya Z, Soos E, Pinter T, Butz H, Horvath Z, et al.
Acta Oncol
. 2024 Jun;
63:433-440.
PMID: 38881341
Aim: The study aims to evaluate the clinical benefit of CGP in our Comprehensive Cancer Center Methods and patients: CGP was introduced into our routine clinical practice in 2021. An...
5.
Incorvaia L, Marques Monteiro F, Massari F, Park S, Roviello G, Fiala O, et al.
Cancer Immunol Immunother
. 2024 Jun;
73(8):142.
PMID: 38832989
Background: There is an ongoing debate as to whether sex could be associated with immune checkpoint inhibitor (ICI) benefit. Existing literature data reveal contradictory results, and data on first-line immune...
6.
Massari F, Santoni M, Takeshita H, Okada Y, Tapia J, Basso U, et al.
Cancer Immunol Immunother
. 2024 Apr;
73(6):106.
PMID: 38634928
Background: Immune checkpoint inhibitors have changed previous treatment paradigm of advanced urothelial carcinoma (UC). The ARON-2 study (NCT05290038) aimed to assess the real-world effectiveness of pembrolizumab in patients recurred or...
7.
Santoni M, Massari F, Takeshita H, Tapia J, Dionese M, Pichler R, et al.
Clin Exp Med
. 2023 Nov;
23(8):5413-5422.
PMID: 37917218
The ARON-2 study (NCT05290038) aimed to assess the real-world efficacy of pembrolizumab in patients recurred or progressed after platinum-based chemotherapy. This retrospective analysis reports the outcomes of urothelial carcinoma (UC)...
8.
Fiala O, Buti S, Takeshita H, Okada Y, Massari F, Palacios G, et al.
Cancer Immunol Immunother
. 2023 Sep;
72(11):3665-3682.
PMID: 37676282
Background: Concomitant medications may potentially affect the outcome of cancer patients. In this sub-analysis of the ARON-2 real-world study (NCT05290038), we aimed to assess the impact of concomitant use of...
9.
Porta C, Bamias A, Zakopoulou R, Myint Z, Cavasin N, Iacovelli R, et al.
Minerva Urol Nephrol
. 2023 Aug;
75(4):460-470.
PMID: 37530662
Background: The upfront treatment of metastatic renal cell carcinoma (mRCC) has been revolutionized by the introduction of immune-based combinations. The role of cytoreductive nephrectomy (CN) in these patients is still...
10.
Santoni M, Buti S, Myint Z, Maruzzo M, Iacovelli R, Pichler M, et al.
Eur Urol Oncol
. 2023 Jul;
7(1):102-111.
PMID: 37481365
Background: Renal c carcinoma (RCC) is one of the most common urinary cancers worldwide, with a predicted increase in incidence in the coming years. Immunotherapy, as a single agent, in...